ASX:1AD
AdAlta Ltd
Location: Australia
ASX
AUD
Common Stock
ISIN: AU0000001AD2
100%
Response Rate
2 of 2 questions answered
Rate Your
Company Satisfaction
Help us improve
Filter:
CR
Christopher Raid4 months ago
How does AdAlta's i-body technology compare to other antibody-based therapies in terms of efficacy and market potential?
AdAlta Ltd4 months ago
- AdAlta’s i-body technology is a tool for drug discovery against drug targets that challenge traditional approaches. i-bodies are very small antibody like molecules that confer the precision of antibody drugs with the ability to access targets traditionally the domain of small molecules. We think for example that this is one of the reasons AD-214, which uses the i-body technology, has been able to demonstrate anti-fibrotic properties against its particular target, a receptor called CXCR4, where other antibodies have generally not been able to do so. AD-214 remains the only product addressing CXCR4 for fibrosis.
- The value of the i-body technology is based on the value of the products it can produce. AD-214 is the most advanced of these and addresses a US$4+b market in idiopathic pulmonary fibrosis and a US$10+b market in kidney fibrosis.
- We have demonstrated efficacy AD-214 in multiple animal models of fibrosis and the planned Phase II clinical study will be the first to study efficacy in human patients
- We have developed other i-body enabled candidates, most notably a world first antibody-like molecule conferring high affinity inhibition of malaria parasite invasion across multiple strains of malaria
We have recently determined that the most effective way to build our clinical stage pipeline rapidly is through in-licensing. We have launched our “East to West” cellular immunotherapy strategy to bring ground-breaking, clinical stage cell therapies for cancer from Asia to western markets via Australia. We have ceased new discovery research using the i-body platform but continue our strategy to realise the value of our existing i-body enabled assets through partnering.
Collaboration with Synthesis BioVentures bridges Asia and West
Adalta Secures $3.7M to Accelerate Growth Strategies
How Adalta Plans to Create Value for Shareholders
Simple business model: in-license Asian cellular immunotherapy for Western markets
New institutional investment enables multiple growth initiatives in parallel
AdCellar bridges Asian cellular immunotherapy innovation to Western markets
AG
Anika G4 months ago
What is the current status of AdAlta's lead candidate, AD-214, in terms of clinical development and potential partnerships?
AdAlta Ltd4 months ago
- AD-214 is a first in class protein therapeutic bringing new hope to patients with fibrotic diseases such as Idiopathic Pulmonary Fibrosis
- AD-214 has completed two Phase I studies in healthy volunteers, establishing the safety profile of the product and helping to confirm our intended Phase II dose
- AdAlta committed that we would finance Phase II studies through out-licensing or co-development/co-investment collaborations, rather than using shareholder equity. We have been seeking such collaborations since the completion of the Phase I clinical studies and continue to have parties evaluating our confidential data.
- It would be neither prudent (for commercial reasons) nor practical (given widely varying timelines to which different parties operate) to forecast timing of any transaction, and of course a transaction is not guaranteed.